LIquid BIopsies in Patients Presenting Non-small Cell Lung Cancer

Summary

The goal of this project is to characterize the genetic profile of patients with advanced stage IIIB/IV non-small cell lung cancer (NSCLC) using liquid biopsies

Eligibility

COHORT 1

Inclusion Criteria:

* Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage IIIB/IV) regardless of the mutation status
* Inclusion at the time of diagnostic
* Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report
* Age ≥ 18 years
* Covered by a health insurance
* Signed consent

Exclusion Criteria:

\- Patients treated before their liquid biopsy

COHORT 2 Inclusion criteria

* Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage IIIB/IV) with one of the following molecular anomalies: Epidermal Growth Factor Receptor (EGFR), B-Raf proto oncogene (BRAF) or Human Epidermal Growth Factor Receptor-2 (HER2) mutations, Anaplatsic Lymphoma Kinase (ALK) or ROS porto-oncogene 1 (ROS1) translocation, Mesenchymal-epithelial transition factor (MET) amplification, RET rearrangement.
* Inclusion at the time of diagnosis
* Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report
* Age ≥ 18 years
* Covered by a health insurance
* Signed consent

COHORT 3 Inclusion criteria

* Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage IIIB/IV) whatever the mutational or PD-L1 status.
* Inclusion at the time of immunotherapy treatment initiation (1st or 2nd line)
* Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report
* Age ≥ 18 years
* Covered by a health insurance
* Signed consent

Exclusion criteria

\- Initiation of immunotherpy before their liquid biopsy

Conditions3

Browse More Trials